Opening book details…
About this Medicine article
P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial by Camidge, D. Ross; Tiseo, Marcello; Ahn, Myung-Ju; Reckamp, Karen; Hansen, Karin; Kim, Sang-We; Huber, Rudolf; West, Howard; Groen, Harry; Hochmair, Maximilian; Leighl, Natasha; Gettinger, Scott; Langer, Corey; Paz-Ares, Luis; Smit, Egbert; Kim, Edward; Reichmann, William; Clackson, Tim; Kerstein, David; Haluska, Frank; Kim, Dong-Wan is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Camidge, D. Ross; Tiseo, Marcello; Ahn, Myung-Ju; Reckamp, Karen; Hansen, Karin; Kim, Sang-We; Huber, Rudolf; West, Howard; Groen, Harry; Hochmair, Maximilian; Leighl, Natasha; Gettinger, Scott; Langer, Corey; Paz-Ares, Luis; Smit, Egbert; Kim, Edward; Reichmann, William; Clackson, Tim; Kerstein, David; Haluska, Frank; Kim, Dong-Wan
- Publisher
- Elsevier ; Elsevier Inc.; Elsevier BV (ISSN 1556-1380)
- Published
- 2017
- Language
- EN
- Field
- Medicine (Health Sciences)